Melbourne-based Immuron (ASX: IMC) has announced the appointment of Dr Leearne Hinch as its new CEO.
Dr Hinch has over two decades of experience in the life science industry, covering general management, strategy, fundraising, commercialisation, business development and marketing.
She has held senior executive and management roles with a number of ASX-listed and privately held companies.
Dr Hinch was most recently the director of Ingeneus Solutions, which provides strategic advice to clients looking to commercialise new life science technologies.
Immuron is focussed on the the development of oral immunotherapy treatments using dairy-derived antibody products for humans.
The company's current products and product candidates are designed to address infectious diseases of the gastrointestinal tract as well as chronic diseases.
Chairman, Dr Roger Aston, said: "The Board welcomes Leearne to Immuron as CEO. She has the leadership, technical and commercial experience to lead the company forward as we globalise our TRAVELAN business and progress our development programs."
Immuron's TRAVELAN is for the prevention of traveller's diarrhoea.
The Board also thanked interim CEO Amos Meltzer for his contribution to the development of Immuron during the past 4.5 years.
Dr Hinch said she was "very excited" to join the company and was looking forward to working with the Board and management to "realise the full potential of Immuron's hyper immune colostrum technology, drive the successful commercialisation of TRAVELAN globally, and advance the NASH/ASH clinical trials towards the Phase 2 milestone."